Tag: Akebia Therapeutics
FDA approves Akebia Therapeutics’ Vafseo for anemia in dialysis patients
In a significant development for the treatment of anemia related to chronic kidney disease (CKD) in dialysis patients, Akebia Therapeutics, Inc. (Nasdaq: AKBA), a pioneering ... Read More